Biotherapeutics company CSL Behring reported on Friday the first patient enrolment under the first clinical trial AEGIS-II (ApoA-I
Event reducinG in Ischemic Syndromes II) following an acute myocardial infarction (MI) and cardiovascular disease, which is the leading cause of death globally.
using a "pre-[beta]1-specific" monoclonal primary antibody (mab55201) for detecting apoA-I
in pre-[beta]1-HDL (13).
Depletion of Rab8 in foam cell inhibits cholesterol efflux to apoA-I
in part by the reduction of ABCA1 level at the PM .
As the major protein component of plasma HDL, apolipoprotein A-I (ApoA-I
) synthesized in the liver and small intestine has been reported to be associated with clinical survival in multiple human cancers, including gastric cancer, nasopharyngeal carcinoma, and breast cancer [14-17].
Besides combined interventions to further increase the LDL-C lowering potential, it can be considered to target at the same time other CHD risk parameters including serum high density lipoprotein (HDL) cholesterol (HDL-C), apolipoprotein A-I (apoA-I
), triacylglycerol or lipoprotein(a) concentrations, and/or blood pressure .
High-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I
), the main proteins of HDL, are antiatherogenic, cardioprotective, and exhibit anti-inflammatory properties.
In endothelial cells, apoA-I
binding to ATPase-B1 causes ATP synthase to hydrolyze ATP into ADP and inorganic phosphate.
Dysfunction of apoA-I
leading to type-2 diabetes was observed to be independent of the apoE genotype (4).
The 299-patient, 12-week, randomized, double-blind ApoA-I
Synthesis Stimulation Evaluation in Patients Requiring Treatment for Coronary Artery Disease (ASSERT) trial showed that the investigational oral small-molecule RVX-208 achieved dose-dependent increases in apoA-I
, HDL, and highly efficient and cardioprotective large-size HDL particles.
* alpha-lipoproteins, or HDL, which contain two to four molecules of apolipoprotein A-I (apoA-I